Comprehensive repository of peer-reviewed clinical trials and preclinical publications investigating Semaglutide.
In a multicenter, double-blind, randomized trial, 17,604 patients 45 years of age or older with preexisting cardiovascular disease and a BMI >= 27 but without diabetes received once-weekly subcutaneous semaglutide (2.4 mg) or placebo. The primary composite cardiovascular endpoint was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Over a mean follow-up of 39.8 months, semaglutide reduced primary endpoint risk by 20% (HR 0.80; 95% CI 0.72-0.90; P<0.001).
In this open-label, 40-week, phase 3 trial, 1,879 patients with type 2 diabetes were randomly assigned in a 1:1:1:1 ratio to receive subcutaneous tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg once weekly. The primary endpoint was the change in glycated hemoglobin level from baseline to 40 weeks. All three doses of tirzepatide demonstrated statistically superior reductions in HbA1c and greater reductions in body weight compared to semaglutide 1 mg.
In this double-blind trial, 1,961 adults with a body-mass index of 30 or greater without diabetes were randomly assigned in a 2:1 ratio to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo, plus lifestyle intervention.
